SCHEMBL3970210

SCHEMBL3970210

Cc1cnc(Cl)nc1-c1cc2ccc(C(=O)O)cc2s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NR1H4 Q96RI1 2/20 0.38
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
IKBKB O14920 2/20 0.37
CHUK O15111 1/20 0.37
IKBKG Q9Y6K9 1/20 0.37
KDM4E B2RXH2 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
HKDC1 Q2TB90 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 1/20 0.36
NFKB1 P19838 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3962466 0.87 HDAC1 (0.48) NPC1RAB9ASMN1; SMN2HDAC3HDAC1
SCHEMBL3968816 0.87 HDAC6 (0.43) NPC1RAB9ASMN1; SMN2HDAC3HDAC1
SCHEMBL3963142 0.87 HDAC6 (0.38) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL3961547 0.81 HPGD (0.51) RAB9ASMN1; SMN2KDM4E
SCHEMBL3969215 0.80 ESR1 (0.38) ESR1ESR2
SCHEMBL3963838 0.78 PIK3CD (0.41) IKBKB
SCHEMBL3964580 0.76 HDAC6 (0.44) NPC1RAB9ASMN1; SMN2HDAC3HDAC1
SCHEMBL3970415 0.76 PDK1 (0.38) NPC1RAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL3965404 0.76 HDAC1 (0.49) NPC1RAB9ASMN1; SMN2HDAC3HDAC1
SCHEMBL22097644 0.74 PDK1 (0.47) RAB9AKDM4ERARARARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG NPC1 2292/4885RAB9A 3349/4885SMN1; SMN2 4233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.